Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
28 févr. 2020 16h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 26, 2020, the Compensation Committee of Esperion’s Board of Directors granted...
Esperion to Participate in Upcoming Investor Conferences
28 févr. 2020 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that the company will participate in fireside chats at the following conferences: Cowen 40th Annual...
Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results
27 févr. 2020 07h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31,...
Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine
21 févr. 2020 16h38 HE
|
Esperion Therapeutics, Inc.
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients –– NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism...
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
31 janv. 2020 07h02 HE
|
Esperion Therapeutics, Inc.
– Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism –– Positive CHMP Opinion is Based...
Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
31 janv. 2020 07h01 HE
|
Esperion Therapeutics, Inc.
– Bempedoic Acid is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism –– Positive CHMP Opinion is Based on the Completed Pivotal Phase 3...
Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
07 janv. 2020 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 janv. 2020 16h15 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion’s Board of Directors granted 358...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
22 nov. 2019 18h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705...
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions
17 nov. 2019 15h05 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American...